Genetically Engineered Lung Cancer Cells for Analyzing Epithelial–Mesenchymal Transition

Kiełbus, Michał; Czapiński, Jakub; Kałafut, Joanna; Woś, Justyna; Stepulak, Andrzej; Rivero-Müller, Adolfo

doi:10.3390/cells8121644

Open AccessArticle

Genetically Engineered Lung Cancer Cells for Analyzing Epithelial–Mesenchymal Transition

by

Michał Kiełbus

¹,

Jakub Czapiński

^1,2,

Joanna Kałafut

¹

,

Justyna Woś

³,

Andrzej Stepulak

¹ and

Adolfo Rivero-Müller

^1,4,*

¹

Department of Biochemistry and Molecular Biology, Medical University of Lublin, 20-093 Lublin, Poland

²

Postgraduate School of Molecular Medicine, 02-091 Warsaw, Poland

³

Department of Clinical Immunology, Medical University of Lublin, 20-093 Lublin, Poland

⁴

Faculty of Natural Sciences and Technology, Åbo Akademi University, 20500 Turku, Finland

^*

Author to whom correspondence should be addressed.

Cells 2019, 8(12), 1644; https://doi.org/10.3390/cells8121644

Submission received: 13 September 2019 / Revised: 6 December 2019 / Accepted: 9 December 2019 / Published: 15 December 2019

(This article belongs to the Section Cellular Pathology)

Download

Browse Figures

Review Reports Versions Notes

Abstract

Cell plasticity, defined as the ability to undergo phenotypical transformation in a reversible manner, is a physiological process that also exerts important roles in disease progression. Two forms of cellular plasticity are epithelial–mesenchymal transition (EMT) and its inverse process, mesenchymal–epithelial transition (MET). These processes have been correlated to the poor outcome of different types of neoplasias as well as drug resistance development. Since EMT/MET are transitional processes, we generated and validated a reporter cell line. Specifically, a far-red fluorescent protein was knocked-in in-frame with the mesenchymal gene marker VIMENTIN (VIM) in H2170 lung cancer cells. The vimentin reporter cells (VRCs) are a reliable model for studying EMT and MET showing cellular plasticity upon a series of stimulations. These cells are a robust platform to dissect the molecular mechanisms of these processes, and for drug discovery in vitro and in vivo in the future.

Keywords: epithelial–mesenchymal transition (EMT); mesenchymal–epithelial transition (MET); cancer cell line; vimentin; reporter

Graphical Abstract

Share and Cite

MDPI and ACS Style

Kiełbus, M.; Czapiński, J.; Kałafut, J.; Woś, J.; Stepulak, A.; Rivero-Müller, A. Genetically Engineered Lung Cancer Cells for Analyzing Epithelial–Mesenchymal Transition. Cells 2019, 8, 1644. https://doi.org/10.3390/cells8121644

AMA Style

Kiełbus M, Czapiński J, Kałafut J, Woś J, Stepulak A, Rivero-Müller A. Genetically Engineered Lung Cancer Cells for Analyzing Epithelial–Mesenchymal Transition. Cells. 2019; 8(12):1644. https://doi.org/10.3390/cells8121644

Chicago/Turabian Style

Kiełbus, Michał, Jakub Czapiński, Joanna Kałafut, Justyna Woś, Andrzej Stepulak, and Adolfo Rivero-Müller. 2019. "Genetically Engineered Lung Cancer Cells for Analyzing Epithelial–Mesenchymal Transition" Cells 8, no. 12: 1644. https://doi.org/10.3390/cells8121644

APA Style

Kiełbus, M., Czapiński, J., Kałafut, J., Woś, J., Stepulak, A., & Rivero-Müller, A. (2019). Genetically Engineered Lung Cancer Cells for Analyzing Epithelial–Mesenchymal Transition. Cells, 8(12), 1644. https://doi.org/10.3390/cells8121644

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Genetically Engineered Lung Cancer Cells for Analyzing Epithelial–Mesenchymal Transition

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI